Author: digi

Non-Compliance with SOPs Leading to Regulatory Audit Findings

August 23, 2025

Non-Compliance with SOPs Leading to Regulatory Audit Findings How SOP Non-Compliance Triggers Regulatory Audit Findings in Clinical Trials Introduction: SOPs as the Backbone of Clinical Compliance Standard Operating Procedures (SOPs) provide the framework for conducting clinical trials in compliance with ICH GCP, FDA 21 CFR Part 312, and EMA guidelines. They define responsibilities, ensure consistency,…

GCP Training & Compliance Audit Findings, Regulatory Audit Findings

SOP for Randomization and Blinding/Unblinding

August 23, 2025

digi

SOP for Randomization and Blinding/Unblinding { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.Clinicalstudies.in/SOP-for-Randomization-and-Blinding-Unblinding” }, “headline”: “SOP for Randomization and Blinding/Unblinding in Clinical Trials”, “description”: “This SOP establishes procedures for randomization, blinding, and unblinding in clinical trials to ensure trial integrity, unbiased results, and compliance with ICH GCP, FDA, EMA, CDSCO, and WHO…

Global SOPs (Applicable to all Agencies), SOP for GCP

Developing Data Visualization Dashboards for Rare Disease Studies

August 23, 2025

digi

Developing Data Visualization Dashboards for Rare Disease Studies Building Effective Data Visualization Dashboards for Rare Disease Clinical Trials The Importance of Visualization in Rare Disease Research Rare disease trials generate highly complex datasets that include genetic information, longitudinal patient outcomes, patient-reported endpoints, and real-world evidence. Unlike large-population trials, the rarity of patients makes every data…

Data & Technology, Rare and Orphan Disease Trials

Regulatory Perspectives on CRO Deviation Handling (FDA, EMA, MHRA)

August 23, 2025

digi

Regulatory Perspectives on CRO Deviation Handling (FDA, EMA, MHRA) Understanding FDA, EMA, and MHRA Perspectives on CRO Deviation Handling Introduction: Why Regulatory Oversight Matters for Deviation Handling Contract Research Organizations (CROs) play a critical role in ensuring clinical trial compliance. As trial activities become increasingly outsourced, regulators such as the U.S. Food and Drug Administration…

CRO Audits, CAPA, and Deviation Management, Deviation Handling in CROs

SOP for China GCP 2020 Alignment and Approvals

August 23, 2025

digi

SOP for China GCP 2020 Alignment and Approvals { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.clinicalstudies.in/china-gcp-2020-alignment-and-approvals” }, “@id”: “https://www.clinicalstudies.in/china-gcp-2020-alignment-and-approvals”, “headline”: “SOP for China GCP 2020 Alignment and Approvals”, “name”: “SOP for China GCP 2020 Alignment and Approvals”, “description”: “Comprehensive SOP describing procedures for aligning with China GCP 2020 and obtaining necessary NMPA…

NMPA — Unique SOPs, SOP for GCP

How Crossover Designs Can Maximize Data in Rare Disease Studies

August 23, 2025

digi

How Crossover Designs Can Maximize Data in Rare Disease Studies Maximizing Efficiency with Crossover Designs in Rare Disease Trials Introduction: Why Crossover Designs Are Ideal for Rare Conditions Rare disease trials often face challenges like small sample sizes, limited geographic distribution, and ethical concerns over placebo use. Crossover trial designs offer a powerful solution—especially when…

Rare and Orphan Disease Trials, Trial Design & Methodology

Compliance Metrics for Trial Sponsors: Tracking Registry Reporting Performance

August 23, 2025

digi

Compliance Metrics for Trial Sponsors: Tracking Registry Reporting Performance Tracking Clinical Trial Disclosure Compliance: Metrics Every Sponsor Should Monitor Why Metrics Matter in Trial Result Disclosure Regulatory agencies such as the FDA and EMA have significantly increased scrutiny of trial result disclosure practices. Sponsors are now expected not only to submit timely and accurate results…

Clinical Trial Registries and Result Disclosure, Results Posting Requirements

Integrating Real-World Evidence in Rare Disease Clinical Trials

August 23, 2025

digi

Integrating Real-World Evidence in Rare Disease Clinical Trials Harnessing Real-World Evidence for Rare Disease Clinical Trial Success Why Real-World Evidence Matters in Rare Disease Studies Rare disease trials often face unique challenges—small sample sizes, heterogeneous patient populations, and ethical concerns with placebo use. Real-world evidence (RWE), derived from electronic health records (EHRs), patient registries, insurance…

Data & Technology, Rare and Orphan Disease Trials

Reducing Trial Burden for Elderly Participants

August 23, 2025

digi

Reducing Trial Burden for Elderly Participants Designing Clinical Trials That Minimize Burden for Older Adults Understanding the Sources of Burden in Elderly Participation Older adults are often underrepresented in clinical research, not due to lack of interest, but because trial protocols create unnecessary burdens. These can include frequent site visits, long travel distances, complex consent…

Pediatric and Geriatric Clinical Trials, Recruitment Strategies

RCA During Regulatory Inspections

August 23, 2025

digi

RCA During Regulatory Inspections Presenting Root Cause Analysis During Regulatory Inspections in Clinical Trials Why RCA Is Critical During Regulatory Inspections In clinical trials, regulatory inspections by agencies like the U.S. FDA, EMA, MHRA, or local health authorities are conducted to assess GCP compliance, subject safety, and data integrity. One of the most scrutinized aspects…

Protocol Deviation and CAPA Management, Root Cause Analysis